D.E. Shaw & Co’s Precigen PGEN Stock Holding History

D.E. Shaw & Co’s Portfolio PGEN Stock Details PGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-50,000	Closed	-$1.21M	–	3568
2017 Q2	$1.21M	Buy	+50,000	New	+$1.1M	﹤0.01%	2298

Other funds holding PGEN

PCM

Patient Capital Management Baltimore, Maryland $2.74B AUM 43.59% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

D.E. Shaw & Co's PGEN Position: Q1 2025 in Review

D.E. Shaw & Co sold out of Precigen (PGEN) in Q1 2025, closing a stake of 424,900 shares — an estimated $476K sold.

D.E. Shaw & Co first reported a position in PGEN in Q4 2013 and held it in 40 quarters. The position peaked at $11.1M in Q2 2017. 138 funds tracked by Wall St. Rank hold PGEN as of Q1 2025.

D.E. Shaw & Co reported no remaining Precigen position as of Q1 2025 after selling out during the quarter.
D.E. Shaw & Co sold 424,900 Precigen shares in Q1 2025, an estimated $476K.
D.E. Shaw & Co first reported a position in Precigen in Q4 2013 and held it in 40 quarters.
D.E. Shaw & Co's Precigen position peaked at $11.1M in Q2 2017.
138 funds tracked by Wall St. Rank held Precigen as of Q1 2025.

Based on D.E. Shaw & Co's 13F filing for Q1 2025, filed 15 May 2025.